Meral Beksac

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi et autres

Abstract Introduction: Triplet or quadruplet regimens, combining proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, are standard of care for newly diagnosed multiple myeloma (MM); however, most patients (pts) eventually experience relapse. At first relapse, there remains a lack of effective treatment options …

ca, tr, cz, gr, ru, au, pl, kr, it, jp, us, gb, es (code pays fourni par la source)

POSTER: MM-1034. Characterization of Ophthalmic Examination Findings and Impact on Reading and Driving in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin

Roman Hájek, Meletios Α. Dimopoulos, Vânia Hungria, Paweł Robak et autres

cz, kr, gr, br, pl, Éthiopie, ru, es, au, us, gb, ca, tr (code pays fourni par la source)

MM-1034: Characterization of Ophthalmic Examination Findings and Impact on Reading and Driving in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin

Roman Hájek, Meletios Α. Dimopoulos, Vânia Hungria, Paweł Robak et autres

cz, kr, gr, br, pl, ru, es, au, us, gb, ca, tr (code pays fourni par la source)

EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Philippe Moreau et autres

gr, it, fr, es, nl, gb, de, be, cz, no, ch, rs, ee, pl, tr, au (code pays fourni par la source)

Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).

Meral Beksac, Hang Quach, Vânia Hungria, Luděk Pour et autres

7544 Background: Belamaf combinations were evaluated for RRMM in the phase 3 DREAMM-7 (belamaf + bortezomib + dexamethasone [BVd]; NCT04246047) and DREAMM-8 (belamaf + pomalidomide + dexamethasone [BPd]; NCT04484623) trials, and significant progression-free survival benefits were reported over standard of care, with …

tr, au, br, cz, kr, ru, es, pl, us, gr (code pays fourni par la source)

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial

Salomon Manier, Meletios Α. Dimopoulos, Xavier P. Leleu, Philippe Moreau et autres

Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) followed …

fr, kr, gr, ca, it, de, us, tr (code pays fourni par la source)

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Heinz Ludwig, Meletios Α. Dimopoulos, Meral Beksac, Frank Bridoux et autres

Introduction: Acute kidney injury (AKI) due to cast nephropathy is a medical emergency that leads to a diagnosis of myeloma in less than 3% of cases, but up to 30% of patients develop kidney impairment during the course of their disease. Currently, …

gr, tr, it, at, gb, us, fr, es (code pays fourni par la source)

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu, Meral Beksac et autres

BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among …

fr (code pays fourni par la source)

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Firoozeh Sahebi, Dirk‐Jan Eikema, Linda Köster, Nicolaus Kröger et autres

Graft-versus-host disease (GVHD) remains among the major causes of treatment failure in patients with multiple myeloma (MM) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The use of post-transplantation cyclophosphamide (PT-Cy) is now a well-established and widely used method for GVHD prophylaxis after HLA …

us, nl, de, es, tr, fr, Afrique du Sud, it, ie (code pays fourni par la source)